RBRC04220 条件を付加する。<br>研究成果の公表にあたっては、笹岡俊邦（基礎生物学研究所）と理研バイオリソースセンターに対して謝辞の表明を必要とする。研究成果の公表にあたって寄託者の指定する文献を引用する(後日指定)。学術機関の学術研究に限る。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 C57BL/6N-Tg(CAG-KO,ChR2/GFP)454-2Sasa/Rbrc C57BL/6N-Tg(CAG-KO,ChR2/GFP)454-2Sasa/Rbrc RIKEN BRC RIKEN BRC true C (3-6 months) C（3〜6か月） Carrier x Noncarrier [C57BL/6NCrlCrlj]. Hemizygous Tg mice are viable and fertile (viability and fertility of homozygotes are unknown). immediate-esrly enhancer [K03104, CMV由来ゲノムDNA配列(クラス2)], loxP sequence [バクテリオファージ由来ゲノムDNA配列(クラス1)], GFP [クラゲ由来cDNA(クラス1)], Kusabira orange [サンゴ由来cDNA(クラス1)], betaglobin, polyA sequerce [M18818, ウサギ由来ゲノムDNA 配列(クラス1)], COP4(Channelrhodopsin-2)[CHLRDRAFT_182032, 緑藻クラミドモナス由来cDNA(クラス1), Fluorescent Proteins/lacZ System Optogenetic transgenic mice. A transgenic construct containing CAG promoter, a loxP-KO (Kusabira Orange)-STOP-loxP sequence and a ChR2 (channelrhodopsin-2)-GFP fusion cDNA was microinjected into C57BL/6NCrlCrlj fertilized eggs. Expression of KO and ChR2/GFP has not been examined yet. Users are encouraged to test the expression pattern and feed back the data for the research community. Developed by National Institute for Basic Biology and RIKEN BioResource Center in 2010. C57BL/6N background. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to Dr. Toshikuni Sasaoka, National Institute for Basic Biology and RIKEN BioResource Center is requested. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. (will be announced) The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol>